Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02RQU
|
|||
Former ID |
DAP000550
|
|||
Drug Name |
Pravastatin
|
|||
Synonyms |
Eptastatin; Oliprevin; Pravastatina; Pravastatine; Pravastatinum; Pravator; Vasten; Pravastatin Sodium Salt; Pravastatina [Spanish]; Pravastatine [French]; Pravastatinum [Latin]; KS-5015; Pravachol (TN); Pravastatin (INN); Pravastatin [INN:BAN]; Pravastatin tert-Octylamine Salt; Pravator (TN); RMS-431; Selektine (TN); SQ-31,000; (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid; (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid; 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypercholesterolaemia [ICD-11: 5C80.0] | Approved | [1], [2] | |
Therapeutic Class |
Anticholesteremic Agents
|
|||
Company |
Bristol-Myers Squibb
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H36O7
|
|||
Canonical SMILES |
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
|
|||
InChI |
1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
|
|||
InChIKey |
TUZYXOIXSAXUGO-PZAWKZKUSA-N
|
|||
CAS Number |
CAS 81093-37-0
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
4962, 7980374, 8183732, 10852022, 14758460, 14880512, 34718661, 46504851, 48416457, 49688762, 49995722, 50718915, 57288813, 57313644, 85789083, 85856288, 93166931, 96025096, 102979949, 104234199, 104305598, 117544687, 118048679, 124899367, 126665388, 129317935, 134337841, 135014686, 135610132, 135650848, 137002685, 142742106, 152034648, 152164597, 160963523, 164814679, 165235255, 174007284, 175266850, 175426985, 175612187, 179148899, 184545482, 187072512, 210279284, 210281607, 223554816, 223682192, 223745588, 226393956
|
|||
ChEBI ID |
CHEBI:63618
|
|||
ADReCS Drug ID | BADD_D01824 ; BADD_D01825 | |||
SuperDrug ATC ID |
C10AA03
|
|||
SuperDrug CAS ID |
cas=081093370
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Target Info | Inhibitor | [3] |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
Superpathway of cholesterol biosynthesis | ||||
Mevalonate pathway | ||||
KEGG Pathway | Terpenoid backbone biosynthesis | |||
Metabolic pathways | ||||
Biosynthesis of antibiotics | ||||
AMPK signaling pathway | ||||
Bile secretion | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
TSH Signaling Pathway | ||||
Panther Pathway | Cholesterol biosynthesis | |||
Pathwhiz Pathway | Steroid Biosynthesis | |||
WikiPathways | Statin Pathway | |||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | ||||
Activation of Gene Expression by SREBP (SREBF) | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Integrated Breast Cancer Pathway | ||||
SREBP signalling | ||||
Cholesterol Biosynthesis |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2953). | |||
REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
REF 3 | A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.